natgillin/translations-raw huggingface dataset:
Sirolimus concentrations were measured in concentration-controlled studies of paediatric renal-transplant patients who were also receiving ciclosporin and corticosteroids. 
Koncentracije sirolimusa so merili v s koncentracijo nadzorovanih študijah pri pediatričnih bolnikih po presaditvi ledvic, ki so prejemali tudi ciklosporin in kortikosteroide.
Before vaccinations, please inform your doctor or pharmacist that you are receiving Rapamune. 
Pred cepljenji obvestite zdravnika ali farmacevta, da prejemate zdravilo Rapamune.
In the patient stratum with baseline calculated GFR above 40 mL/min, renal function was not improved overall. 
V skupini bolnikov z izhodiščno izračunano GFR, večjo od 40 ml/min, se ledvična funkcija na splošno ni izboljšala.
In patients for whom ciclosporin withdrawal is either unsuccessful or cannot be attempted, the combination of ciclosporin and Rapamune should not be maintained for more than 3 months post-transplantation. 
Pri bolnikih, pri katerih je ukinjanje ciklosporina neuspešno ali ga ni mogoče izvesti, lahko kombinirano zdravljenje z zdravilom Rapamune in ciklosporinom traja največ 3 mesece po presaditvi.
Information directly related to the tablet formulation is summarised specifically in the Oral tablet section. 
Podatki, ki se nanašajo neposredno na tablete, pa so povzeti v poglavju Peroralne tablete.
No dose adjustment is required (see section 5.2). 
Okvara ledvic Prilagoditev odmerka ni potrebna (glejte poglavje 5.2).
any high blood pressure medicines or medicines for heart problems including nicardipine, verapamil and diltiazem. 
katerakoli zdravila za zdravljenje zvišanega krvnega tlaka ali bolezni srca, vključno z nikardipinom, verapamilom in diltiazemom.
What you need to know before you take Rapamune 
Kaj morate vedeti, preden boste vzeli zdravilo Rapamune
The changes may be related to chronic immunosuppression. 
Te spremembe so lahko posledica kroničnega zaviranja imunske odzivnosti.
No other liquids, including grapefruit juice, should be used for dilution. 
Drugih tekočin, še posebno soka grenivke, ne uporabljajte za razredčenje.
Patients initiated on ramipril 10 mg had a higher rate of BCAR (15%) compared to patients initiated on ramipril 5 mg (5%). 
Pri bolnikih z začetnim odmerkom ramiprila 10 mg je bil delež tistih z BCAR večji (15 %) kot pri bolnikih z začetnim odmerkom ramiprila 5 mg (5 %).
The difference in bioavailability was less marked upon steady-state administration to renal transplant recipients, and therapeutic equivalence has been demonstrated in a randomised study of 477 patients. 
Razlika v biološki uporabnosti je pri bolnikih s presajeno ledvico manj izrazita v stanju dinamičnega ravnovesja, terapevtsko ekvivalentnost pa so pokazali v randomizirani študiji pri 477 bolnikih.
Most patients were on immunosuppressive regimens, which included Rapamune in combination with other immunosuppressive agents. 
Večina bolnikov je bila zdravljenih po imunosupresivnih shemah, ki so vključevale zdravilo Rapamune v kombinaciji z drugimi imunosupresivnimi zdravili.
TEXT FOR 60 mL OUTER CARTON (CONTAINING SYRINGES/BOTTLE IN CARTON) 
BESEDILO ZA 60 ml ŠKATLO (VSEBUJE BRIZGE/STEKLENICO V ŠKATLI)
The safety and efficacy of Rapamune in children and adolescents less than 18 years of age have not been established. 
Varnost in učinkovitost zdravila Rapamune pri otrocih in mladostnikih, mlajših od 18 let, nista bili dokazani.
24 hours in the dosing syringe (at room temperature, but not to exceed 25C). 
24 ur v odmerni brizgi (pri sobni temperaturi, vendar ne višji od 25 °C)
Currently in clinical practice, sirolimus whole blood concentrations are being measured by both chromatographic and immunoassay methodologies. 
Trenutno se v klinični praksi koncentracija sirolimusa v polni krvi meri tako s kromatografskimi kot tudi z imunološkimi metodami.
Once Rapamune maintenance dose is adjusted, patients should continue on the new maintenance dose for at least 7 to 14 days before further dosage adjustment with concentration monitoring. 
Po prilagoditvi vzdrževalnega odmerka zdravila Rapamune morajo bolniki novi vzdrževalni odmerek jemati vsaj 7 do 14 dni pred nadaljnjim prilagajanjem odmerka, pri čemer je treba spremljati koncentracijo zdravila.
Your doctor will perform tests to monitor the levels of Rapamune in your blood. 
Zdravnik bo z laboratorijskimi preiskavami spremljal raven zdravila Rapamune v vaši krvi.
So if you are taking Rapamune, you may therefore catch more infections than usual, such as infections of the skin, mouth, stomach and intestines, lungs and urinary tract (see list below). 
Če jemljete zdravilo Rapamune, boste lahko zato dobili več okužb kot ponavadi, na primer okužbe kože, ust, želodca in črevesa, pljuč in sečil (glejte seznam v nadaljevanju).
There was a higher rate of serious adverse events, including pneumonia, acute rejection, graft loss and death, in this sirolimus treatment arm (n=60, median time post-transplant 36 months). 
Delež resnih neželenih učinkov, vključno s pljučnico, akutno zavrnitvijo, izgubo presadka in smrtjo, je bil namreč v tej podskupini, zdravljeni s sirolimusom, večji (n = 60, mediani čas po presaditvi je 36 mesecev).
Multiples of the 0.5 mg tablets should therefore not be used as a substitute for other tablet strengths. 
Zato se več 0,5 mg tablet ne sme uporabljati za nadomeščanje drugih jakosti tablet.
It is recommended that Rapamune be administered 4 hours after ciclosporin (microemulsion). 
Priporočljivo je, da zdravilo Rapamune damo 4 ure po ciklosporinu (mikroemulzija).
If it is necessary to carry your medication with you, fill the dosing syringe to the appropriate mark and place a cap securely on it - the cap should snap into place. 
Če morate zdravilo vzeti s seboj, napolnite brizgo do predpisane oznake in nanjo namestite zaščitni pokrovček - pokrovček se zaskoči na svoje mesto.
The rate of death in the sirolimus conversion group was higher than the CNI continuation group, although the rates were not significantly different. 
Stopnja smrtnosti v skupini s prehodom na sirolimus je bila večja kot v skupini, ki je nadaljevala s CNI, vendar razlika ni bila statistično pomembna.
Loss of TSC gene function activates the mTOR signaling pathway, resulting in cellular proliferation and release of lymphangiogenic growth factors. 
Izguba funkcije gena za KTS aktivira signalno pot mTOR, kar povzroči proliferacijo celic in sproščanje limfangiogenih rastnih dejavnikov.
Once in the syringe the medication may be kept at room temperature (not exceeding 25C) or refrigerated and should be used within 24 hours. 
Zdravilo v odmerni brizgi lahko shranjujte pri sobni temperaturi (ne nad 25 C) ali v hladilniku in ga morate porabiti v 24 urah.
In mouse, chronic ulcerative skin lesions were increased. 
Pri miših so opazili večjo pogostnost kroničnih ulceroznih lezij na koži.
Optimally, adjustments in Rapamune dose should be based on more than a single trough level obtained more than 5 days after a previous dosing change. 
Optimalno je, da prilagoditve odmerka zdravila Rapamune temeljijo na več kot eni najmanjši koncentraciji v stanju dinamičnega ravnovesja, ugotovljeni več kot 5 dni po predhodni spremembi odmerjanja.
LAM involves lung tissue infiltration with smooth muscle-like cells that harbour inactivating mutations of the tuberous sclerosis complex (TSC) gene (LAM cells). 
LAM vključuje infiltracijo pljučnega tkiva s celicami, podobnimi celicam gladkih mišic, v katerih so prisotne inaktivirajoče mutacije gena za kompleks tuberozne skleroze (KTS) (celice LAM).
The simultaneous oral administration of 10 mg of Rapamune oral solution and 120 mg of diltiazem significantly affected the bioavailability of sirolimus. 
Sočasna uporaba 10 mg peroralne raztopine zdravila Rapamune in 120 mg diltiazema je bistveno spremenila biološko uporabnost sirolimusa.
Withdraw the exact amount of Rapamune oral solution as prescribed by your doctor by gently pulling out the plunger of the dosing syringe until the level of the oral solution is even with the appropriate mark on the dosing syringe. 
Odvzemite točno tako količino zdravila Rapamune peroralne raztopine, kot vam jo je predpisal zdravnik, tako da počasi izvlečete bat iz odmerne brizge, dokler nivo peroralne raztopine ni poravnan z želeno oznako na odmerni brizgi.
Since half-life is prolonged in these patients, therapeutic monitoring of the medicinal product after a loading dose or a change of dose should be performed for a prolonged period of time until stable concentrations are reached (see sections 4.2 and 5.2). 
Ker je razpolovni čas pri teh bolnikih podaljšan, je po polnilnem odmerku ali spremembi odmerka potrebno dolgotrajno terapevtsko spremljanje koncentracije zdravila, dokler niso dosežene stabilne koncentracije (glejte poglavji 4.2 in
Please inform your doctor if you are taking medicines to lower your blood fats. 
Obvestite zdravnika, če jemljete zdravila za zniževanje ravni maščob v krvi.
anti-epileptic medicines including carbamazepine, phenobarbital, phenytoin. 
zdravila za zdravljenje epilepsije, vključno s karbamazepinom, fenobarbitalom, fenitoinom.
At 48 months, there was a statistically significant difference in graft survival in favour of the Rapamune following ciclosporin elimination group compared to the Rapamune with ciclosporin therapy group (including and excluding loss to follow-up). 
Po 48 mesecih je bila razlika v preživetju presadka statistično pomembna v korist skupine z zdravilom Rapamune po ukinitvi ciklosporina v primerjavi s skupino, ki se je zdravila z zdravilom Rapamune in ciklosporinom (ne glede na vključenost ali izključenost bolnikov, izgubljenih za spremljanje).
In rat, testicular interstitial cell adenomas were likely indicative of a species-dependent response to lutenising hormone levels and are usually considered of limited clinical relevance. 
Pri podganah so intersticijski adenomi testisov zelo verjetno posledica od vrste odvisnega odgovora na ravni luteinizirajočega hormona in običajno nimajo večjega kliničnega pomena.
After a single dose of [14C] sirolimus in healthy volunteers, the majority (91.1%) of radioactivity was recovered from the faeces, and only a minor amount (2.2%) was excreted in urine. 
C označenega sirolimusa pri zdravih prostovoljcih so večino radioaktivnosti (91,1 %) izmerili v blatu in le manjšo količino (2,2 %) v urinu.
For patients with S-LAM, the initial Rapamune dose should be 2 mg/day. 
Pri bolnikih s S-LAM mora biti začetni odmerek zdravila Rapamune 2 mg/dan.
Uncommon (≥1/1,000 to 
Občasni (≥ 1/1.000 do
You may have been instructed to take your Rapamune oral solution at a particular time of day. 
Morda so vam svetovali, da jemljete zdravilo Rapamune peroralno raztopino ob točno določenem času.
Nephrotic syndrome (see section 4.4); Focal segmental glomerulosclerosis* 
Bolezni sečil proteinurija nefrotski sindrom (glejte poglavje 4.4), fokalna segmentna glomeruloskleroz a*
The mean calculated glomerular filtration rate (GFR) at 12, 24, 36, 48 and 60 months was significantly higher for patients receiving Rapamune following ciclosporin elimination than for those in the Rapamune with ciclosporin therapy group. 
Povprečna izračunana hitrost glomerulne filtracije (GFR) pri 12, 24, 36, 48 in 60 mesecih je bila pri bolnikih, ki so prejemali zdravilo Rapamune po ukinitvi ciklosporina pomembno večja kot pri tistih, ki so se zdravili z zdravilom Rapamune in ciklosporinom.
Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. 
Zdravilo Rapamune je indicirano za preprečevanje zavrnitve organa pri odraslih bolnikih z nizkim do zmernim imunološkim tveganjem pri presaditvi ledvice.
After dilution, the preparation should be used immediately. 
Po redčenju pripravek uporabite takoj.
In two clinical studies in de novo liver transplant patients, the use of sirolimus plus ciclosporin or tacrolimus was associated with an increase in hepatic artery thrombosis, mostly leading to graft loss or death. 
V dveh kliničnih študijah pri bolnikih s presadki jeter de novo je bila uporaba sirolimusa s ciklosporinom ali takrolimusom povezana s porastom tromboze jetrne arterije, ki je večinoma vodila v izgubo presadka ali smrt.
If you take more Rapamune than you should 
Če ste vzeli večji odmerek zdravila Rapamune, kot bi smeli
Store in the original bottle in order to protect from light. 
Shranjujte v originalni steklenici za zagotovitev zaščite pred svetlobo.
This medicine contains approximately 350 mg propylene glycol (E1520) in each mL. 
To zdravilo vsebuje približno 350 mg propilenglikola (E1520) na 1 ml.
Experimental evidence suggests that sirolimus binds to the specific cytosolic protein FKPB-12, and that the FKPB 12-sirolimus complex inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a critical kinase for cell cycle progression. 
Eksperimentalni dokazi kažejo, da se sirolimus veže na specifično beljakovino FKPB-12 v citosolu in da nastali kompleks sirolimus-FKPB-12 zavira aktivacijo tarče rapamicina pri sesalcih (mTOR mammalian Target of Rapamycin), kinaze, ki je ključna za nadaljevanje celičnega cikla pri sesalcih.
In animals, sirolimus has a direct effect on T- and B-cell activation, suppressing immune-mediated reactions, such as allograft rejection. 
Pri živalih sirolimus deluje neposredno na aktivacijo limfocitov T in B in tako zavira imunsko posredovane reakcije, kot je zavrnitev alogenega presadka.
If bubbles form in the oral solution in the dosing syringe during withdrawal, empty the Rapamune solution back into the bottle and repeat the withdrawal procedure. 
Če se med odvzemom raztopine v peroralni raztopini v odmerni brizgi pojavijo mehurčki, izpraznite raztopino nazaj v steklenico in postopek ponovite.
Although sirolimus inhibits human liver microsomal cytochrome P450 CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 in vitro, the active substance is not expected to inhibit the activity of these isozymes in vivo since the sirolimus concentrations necessary to produce inhibition are much higher than those observed in patients receiving therapeutic doses of Rapamune. 
V in vitro poskusih sirolimus zavira humani jetrni mikrosomski citokrom P450 CYP2C9, CYP2C19, CYP2D6 in CYP3A4/5, vendar ni pričakovati, da bi učinkovina zavirala aktivnost teh izoencimov tudi in vivo, saj so koncentracije sirolimusa, potrebne za inhibicijo, mnogo večje od tistih, ki jih izmerijo pri bolnikih, ki prejemajo terapevtske odmerke zdravila Rapamune.
When given 2 hours before CsA administration, sirolimus Cmax and AUC were not affected. 
Uporaba sirolimusa 2 uri pred uporabo CsA ni vplivala na vrednosti Cmax in AUC sirolimusa.
It is not necessary to modify the Rapamune loading dose. 
Polnilnega odmerka ni treba prilagoditi.
The blood to plasma ratio (B/P) of 36 indicates that sirolimus is extensively partitioned into formed blood elements. 
Razmerje koncentracij sirolimusa v krvi in plazmi (B/P - Blood to Plasma ratio) je 36, kar kaže, da sirolimus obširno prehaja v krvne celice.
This amount of alcohol may be harmful for those suffering from alcoholism as well as for pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease, or epilepsy. 
Ta odmerek alkohola bi utegnil škodovati alkoholikom, pa tudi nosečnicam ali doječim materam, otrokom in skupinam z velikim tveganjem, kot so bolniki z boleznijo jeter ali epilepsijo.
Rapamune oral solution contains polysorbate-80, which is known to increase the rate of di-(2-ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC). 
Zdravilo Rapamune peroralna raztopina vsebuje polisorbat 80, za katerega je znano, da poveča izločanje di-(2-etilheksil)ftalata (DEHP) iz polivinil klorida (PVC).
Rapamune is for oral use only. 
Zdravilo Rapamune je samo za peroralno uporabo.
Sirolimus administered concomitantly (5 mg), and at 2 hours (5 mg) and 4 hours (10 mg) after CsA (300 mg), resulted in increased sirolimus AUC by approximately 183%, 141% and 80%, respectively. 
Uporaba sirolimusa sočasno s CsA (5 mg), 2 uri (5 mg) ali 4 ure (10 mg) po dajanju CsA (300 mg), je povečala vrednost AUC sirolimusa za približno 183 %, 141 % oziroma 80 %.
Sirolimus is the major component in human whole blood and contributes to greater than 90% of the immunosuppressive activity. 
V polni krvi pri človeku prevladuje sirolimus, ki prispeva več kot 90 % učinka zaviranja imunske odzivnosti.
Rapamune tablets administered to 12 renal transplant patients above 65 years of age gave similar results to adult patients (n=167) 18 to 65 years of age. 
Tablete zdravila Rapamune, dane 12 bolnikom s presajeno ledvico, starejšim od 65 let, so dale podobne rezultate kot pri odraslih bolnikih (n = 167), starih 18 do 65 let.
Sirolimus levels should be monitored and appropriate dose reductions of both medicinal products should be considered. 
Ravni sirolimusa je treba spremljati in po potrebi ustrezno zmanjšati odmerka obeh zdravil.
Administration of multiple doses of rifampicin decreased sirolimus whole blood concentrations following a single 10 mg dose of Rapamune oral solution. 
Dajanje večkratnih odmerkov rifampicina je zmanjšalo koncentracije sirolimusa v polni krvi po enkratnem 10 mg odmerku peroralne raztopine zdravila Rapamune.
In addition, re-transplant recipients whose previous grafts survived for at least 6 months after transplantation were included. 
Vključili so tudi bolnike po ponovni presaditvi, pri katerih se je prejšnja presajena ledvica ohranila vsaj 6 mesecev po presaditvi.
Rapamune should be given with corticosteroids. 
Zdravilo Rapamune je treba uporabljati skupaj s kortikosteroidi.
The concomitant administration of Rapamune and angiotensin-converting enzyme (ACE) inhibitors has resulted in angioneurotic oedema-type reactions. 
Sočasna uporaba zdravila Rapamune in zaviralcev angiotenzinske konvertaze (ACE - AngiotensinConverting Enzyme) je povzročila reakcije vrste angionevrotičnega edema.
In most patients, dose adjustments can be based on simple proportion: new Rapamune dose=current dose x (target concentration/current concentration). 
Pri večini bolnikov lahko prilagoditve odmerka temeljijo na preprostem razmerju: novi odmerek zdravila Rapamune = dosedanji odmerek x (ciljna koncentracija/sedanja koncentracija).
Multiples of 0.5 mg tablets should not be used as a substitute for 1 mg and 2 mg tablets, as the different strengths are not directly interchangeable. 
Več 0,5 mg tablet ne smete uporabljati kot nadomestilo za 1 mg ali 2 mg tablete, ker različne jakosti med seboj niso neposredno zamenljive.
Ciclosporin was not withdrawn in patients experiencing Banff Grade 3 acute rejection episodes, who were dialysis-dependent, who had a serum creatinine higher than 400 mol/L, or who had inadequate renal function to support ciclosporin withdrawal. 
Ciklosporina niso ukinili pri bolnikih, ki so imeli akutno zavrnitveno reakcijo stopnje 3 po Banffu, pri tistih, ki so bili odvisni od dialize, tistih, ki so imeli serumski kreatinin višji od 400 mol/l, ali tistih, ki so imeli nezadostno delovanje ledvic, da bi lahko prenesli ukinitev ciklosporina.
If you forget to take Rapamune 
Če ste pozabili vzeti zdravilo Rapamune
Rapamune, like other immunosuppressive medicines, may decrease your body's ability to fight infection, and may increase the risk of developing cancer of the lymphoid tissues and skin. 
zdravilo Rapamune, tako kot tudi druga zdravila za zaviranje imunske odzivnosti, lahko zmanjša sposobnost vašega organizma za obrambo pred okužbami in lahko zveča tveganje za nastanek raka limfnega tkiva in kože.
Sirolimus is extensively metabolised by the CYP3A4 isozyme in the intestinal wall and liver. 
Sirolimus se obširno presnavlja preko izoencima CYP3A4 v črevesni steni in jetrih.
Grapefruit juice should be avoided (see section 4.5). 
Bolniki se morajo izogibati soku grenivke (glejte poglavje 4.5).
Controlled clinical studies with posology comparable to that currently indicated for the use of Rapamune in adults have not been conducted in children or adolescents below 18 years of age. 
Nadzorovane klinične študije z odmerki, primerljivimi s tistimi, ki se trenutno uporabljajo pri zdravljenju z zdravilom Rapamune pri odraslih, pri otrocih ali mladostnikih, mlajših od 18 let, niso bile izvedene.
Subjects were to receive Rapamune (sirolimus target concentrations of 5 to 15 ng/mL) in combination with a calcineurin inhibitor and corticosteroids or to receive calcineurin-inhibitor-based immunosuppression without Rapamune. 
Preskušanci so prejeli bodisi zdravilo Rapamune (ciljne koncentracije sirolimusa od 5 do 15 ng/ml) sočasno z zaviralcem kalcinevrina in kortikosteroidi bodisi imunosupresijo na osnovi zaviralca kalcinevrina brez zdravila Rapamune.
The rates of acute rejection, graft loss, and death were similar, but urinary protein excretion was increased in the Rapamune treatment arm of this subset. 
Pogostnost akutne zavrnitve, izgube presadka in smrti je bila podobna, izločanje beljakovin v urin pa se je v podskupini, ki je prejemala zdravilo Rapamune, zvečalo.
Clinical studies of Rapamune did not include a sufficient number of patients above 65 years of age to determine whether they will respond differently than younger patients. 
V klinične študije zdravila Rapamune ni bilo vključenih dovolj bolnikov, starejših od 65 let, da bi lahko ugotovili, ali se le-ti na zdravljenje odzivajo drugače kot mlajši bolniki.
The tablets are supplied in blister packs of 30 and 100 tablets. 
Tablete so na voljo v pretisnem omotu s 30 ali 100 tabletami.
Adjustments to the targeted range should be made according to the assay being utilised to determine the sirolimus trough concentrations. 
Ciljni razpon je treba prilagajati v skladu z metodo, uporabljeno za določanje najmanjših koncentracij sirolimusa.
Sirolimus is a substrate for both cytochrome P450 IIIA4 (CYP3A4) and P-glycoprotein. 
Sirolimus je substrat tako za citokrom P450 IIIA4 (CYP3A4) kot za P-glikoprotein.
Based upon the analysis of data from 36 months and beyond, which showed a growing difference in graft survival and renal function, as well as significantly lower blood pressure in the ciclosporin elimination group, it was decided to discontinue subjects from the Rapamune with ciclosporin group. 
Na podlagi analize podatkov po 36. mesecu, ki je pokazala naraščajočo razliko v preživetju presadka in ledvičnem delovanju, pa tudi pomembno nižji krvni tlak v skupini po ukinitvi ciklosporina, so se odločili za izključitev preskušancev iz skupine, ki je prejemala zdravilo Rapamune in ciklosporin.
Much of the general pharmacokinetic information was obtained using the Rapamune oral solution, which is summarised first. 
Veliko splošnih farmakokinetičnih podatkov so pridobili v študijah s peroralno raztopino zdravila Rapamune, zato so ti povzeti najprej.
Clinical studies with Rapamune oral solution did not include a sufficient number of patients above 65 years of age to determine whether they will respond differently than younger patients (see section 5.2). 
Klinične študije s peroralno raztopino zdravila Rapamune niso vključevale zadostnega števila bolnikov, starejših od 65 let, za določitev ali se ti na sirolimus odzivajo drugače kot mlajši bolniki (glejte poglavje 5.2).
The terminal half-life in stable renal transplant patients after multiple oral doses was 62  16 hours. 
Končni razpolovni čas pri stabilnih bolnikih po presaditvi ledvice po večkratnih peroralnih odmerkih je znašal 62 ± 16 ur.
Because of the potential for adverse reactions in breast-fed infants from sirolimus, breast-feeding should be discontinued during treatment with Rapamune. 
Zaradi možnosti pojava neželenih učinkov sirolimusa pri dojenih otrocih, je med zdravljenjem z zdravilom Rapamune priporočljivo prenehati z dojenjem.
Special populations Black population 
Pripadniki črne rase
Inhibitors of P-gp may decrease the efflux of sirolimus from intestinal cells and increase sirolimus levels. 
Zaviralci P-gp lahko zmanjšajo izločanje sirolimusa iz črevesnih celic in povečajo koncentracije sirolimusa.
Pale yellow to yellow solution. 
peroralna raztopina bledo rumena do rumena raztopina
The continued co-administration of ciclosporin and Rapamune as maintenance therapy cannot be recommended. 
Nadaljevanje sočasnega zdravljenja s ciklosporinom in zdravilom Rapamune kot vzdrževalno zdravljenje ni priporočljivo.